Search Results 21-30 of 2956 for Erleada

  1. Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer - Mayo Clinic

    Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body. Akt ...

  2. https://www.mayoclinic.org/spanish_patient_consumer_web.xml

  3. Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma - Mayo Clinic

    Regorafenib is a type of drug called a kinase inhibitor. Regorafenib interferes with how some kinase proteins work. Some of these kinases in cancer cells might ...

  4. Lerodalcibep-liga (subcutaneous route) - Side effects & dosage - Mayo Clinic

    Lerodalcibep-liga injection is used together with a proper diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in patients with ...

  5. Encorafenib (oral route) - Mayo Clinic

    Encorafenib is also used in combination with binimetinib to treat non-small cell lung cancer (NSCLC) that has spread in patients who have BRAF V600E mutations.

  6. https://www.mayoclinic.org/patient_consumer_web.xml

  7. https://www.mayoclinic.org/spanish_patient_consumer_faq.xml

  8. Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  9. https://www.mayoclinic.org/chinese_patient_consumer_web.xml

  10. A Study To Evaluate The Impact On Metastases-free Survival With The Addition Of Saruparib Versus Placebo To A Standard Radiotherapy/androgen Deprivation Regimen In Men With High-risk Prostate Cancer With A BRCA Mutation. - Mayo Clinic

    The purpose of the study is to evaluate the impact on metastases-free survival with the addition of saruparib versus placebo to a standard RT + ADT regimen in ...